Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aerie Pharmaceuticals (NQ: AERI ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Nov 18, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Aerie Pharmaceuticals < Previous 1 2 Next > Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business November 22, 2022 From Alcon Inc. Investors Via Business Wire Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results November 03, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI October 14, 2022 From Kahn Swick & Foti, LLC Via Business Wire Small-Cap Catalyst Pharma Is Among Market's Best Price Performers October 04, 2022 Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month. Via MarketBeat Topics Stocks Exposures US Equities Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options September 13, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI August 24, 2022 From Kahn Swick & Foti, LLC Via Business Wire AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareholders August 24, 2022 From Halper Sadeh LLP Via Business Wire Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million August 23, 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of Via Spotlight Growth Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio August 22, 2022 From Alcon Inc. Investors Via Business Wire Aerie Pharmaceuticals Announces New Employee Inducement Grant August 15, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update August 04, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease August 01, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET July 28, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Announces New Employee Inducement Grant July 08, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET May 25, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease May 24, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update May 05, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET April 28, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022 April 26, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022 April 20, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET April 06, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer March 18, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update February 24, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer February 24, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET February 17, 2022 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4) December 22, 2021 From Aerie Pharmaceuticals Via Business Wire Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer December 16, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions December 07, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences November 09, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update November 04, 2021 From Aerie Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.